20 articles
Clinical trial tests whether senolytic compounds can reduce cellular aging burden and improve bone health markers in older adults.
Small trial tests hormone-based therapy to combat age-related muscle and bone loss in vulnerable adults.
A completed Mayo Clinic trial examined whether nicotinamide riboside can preserve bone density, muscle mass, and metabolic function in healthy older adults.
NIDCR researchers compared stromal cells from bone marrow, skin, spleen, and fat to identify which best regenerates bone and supports blood formation.
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
Clinical trial tests safety of combined prebiotic-probiotic supplement in 32 healthy participants over 5 months.
French study explores how tiny cellular packages in blood could predict cancer recurrence and guide treatment decisions.
A Phase 2 trial tests once-daily oral resmetirom (MGL-3196) against placebo to reduce LDL-C in patients with inherited high cholesterol.
A completed Nestlé-sponsored trial directly compared three popular NAD precursors head-to-head in healthy adults.
Researchers explored whether cancer-derived cell-free DNA and telomere maintenance mutations could serve as early warning biomarkers in soft tissue sarcoma patients.
New study evaluates reduced nicotinamide mononucleotide for anti-aging benefits, measuring biological age and physical performance.
A completed RCT tests whether adding collagen peptides to standard calcium and vitamin D supplementation improves bone density and remodeling markers in women with osteopenia.
Small study tested optical breast scanner to identify women at risk for hormone therapy-induced breast cancer within months of treatment.
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
A landmark Phase 3 trial evaluates whether omecamtiv mecarbil, a cardiac myosin activator, reduces cardiovascular death in HFrEF patients.
Study reveals how lean people can still have obesity-like metabolism and whether calorie restriction helps reverse this dangerous condition.
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
A terminated RCT explored whether immunotype-targeted supplements could reduce iAge®, an AI-derived biomarker of chronic inflammation and immune aging.
120-person trial tested whether Oligonol could reduce muscle loss and cardiovascular risks in middle-aged and older adults.
